Bio Nebraska signs letter opposing an expanded TRIPS waiver

Bio Nebraska joined other state associations in submitting a letter to President Biden expressing concerns with the proposed expansion of the TRIPS Waiver Form to include therapeutics and diagnostics.

Bio Nebraska joined this letter because allowing foreign competitors unfettered access to the intellectual property of our country’s biotechnology innovators would be harmful for American competitiveness and would do nothing to address the challenges of the COVID-19 pandemic worldwide. The letter explains in greater detail the industry’s concerns with an expanded TRIPS waiver.